Drug Type Monoclonal antibody |
Synonyms anti-HER3 monoclonal antibody(Shanghai Institute of Biological Products), SIBP 03, SIBP-03 + [1] |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | China | 27 Sep 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 26 Nov 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | IND Approval | China | 21 Jun 2024 | |
Squamous cell carcinoma of head and neck metastatic | IND Approval | China | 21 Jun 2024 |